|Edoxaban versus warfarin in patients with atrial fibrillation|
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
|Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study|
D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ...
Arthritis & Rheumatism 65 (3), 559-570, 2013
|Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an …|
R Fleischmann, M Cutolo, MC Genovese, EB Lee, KS Kanik, S Sadis, ...
Arthritis & Rheumatism 64 (3), 617-629, 2012
|Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised …|
PJ Mease, D van der Heijde, CT Ritchlin, M Okada, RS Cuchacovich, ...
Annals of the rheumatic diseases 76 (1), 79-87, 2017
|A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid …|
JM Kremer, S Cohen, BE Wilkinson, CA Connell, JL French, ...
Arthritis & Rheumatism 64 (4), 970-981, 2012
|Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial|
J Vestbo, JA Anderson, RD Brook, PMA Calverley, BR Celli, C Crim, ...
The Lancet 387 (10030), 1817-1826, 2016
|A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy|
P Emery, J Vencovský, A Sylwestrzak, P Leszczyński, W Porawska, ...
Annals of the rheumatic diseases 76 (1), 51-57, 2017
|Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)|
D Isenberg, C Gordon, D Licu, S Copt, CP Rossi, D Wofsy
Annals of the rheumatic diseases 74 (11), 2006-2015, 2015
|Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo‐controlled trial|
RF Van Vollenhoven, N Kinnman, E Vincent, S Wax, J Bathon
Arthritis & Rheumatism 63 (7), 1782-1792, 2011
|A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid …|
JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, ...
Annals of the Rheumatic Diseases 76 (1), 58-64, 2017
|Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial|
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
|Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose …|
A Kavanaugh, J Kremer, L Ponce, R Cseuz, OV Reshetko, ...
Annals of the rheumatic diseases 76 (6), 1009-1019, 2017
|Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis|
A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ...
Arthritis & Rheumatology 71 (2), 258-270, 2019
|Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials|
MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ...
Arthritis & rheumatology 69 (2), 362-375, 2017
|Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3 …|
ME Weinblatt, CO Bingham, AM Mendelsohn, L Kim, M Mack, J Lu, ...
Annals of the rheumatic diseases 72 (3), 381-389, 2013
|Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …|
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
|A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite …|
JS Smolen, SK Agarwal, E Ilivanova, XL Xu, Y Miao, Y Zhuang, I Nnane, ...
Annals of the rheumatic diseases 76 (5), 831-839, 2017
|Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled …|
P Mease, LC Coates, PS Helliwell, M Stanislavchuk, ...
The Lancet 392 (10162), 2367-2377, 2018
|Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with …|
JS Smolen, JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, ...
Annals of the rheumatic diseases 77 (2), 234-240, 2018
|Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials|
D Khanna, CP Denton, PA Merkel, T Krieg, FO Le Brun, A Marr, ...
Jama 315 (18), 1975-1988, 2016